U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients ...

Zymeworks has won the Food and Drug Administration's fast-track designation for its ZW191 antibody-drug conjugate for patients with advanced or metastatic platinum-resistant ovarian cancer.

The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...

Zymeworks Inc. recently announced that the U.S. FDA granted Fast Track designation to ZW191, its folate receptor-α–targeting antibody-drug conjugate, for patients with advanced or metastatic ...

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments. The U.S. Food and Drug Administration (FDA) ...